AstraZeneca Pharma India Limited — Updates, 11-02-2025: Press Release

AstraZeneca Pharma India Ltd has reported a robust 44% increase in revenue for the third quarter, driven by significant growth across its therapeutic areas. Total revenue from operations reached Rs. 1,345 Mn, marking an upward trend compared to the same period last year. The oncology segment excelled with a 67% growth, while biopharmaceuticals recorded a 10% increase. The company has secured 13 approvals since 2023, enhancing its product offerings, including the launch of Budesonide in January 2025 for COPD treatment.

Management emphasized a commitment to innovation and accessibility, aiming to meet unmet patient needs effectively. Alongside these advancements, AstraZeneca is focused on enhancing healthcare resilience in India.

Recent appointments in the company and notable recognitions, such as being named a 'Great Place To Work' for the seventh consecutive year, underline its commitment to fostering a positive work environment and driving industry success. Investors should note this strong performance and strategic focus as indicative of potential growth opportunities in the biopharmaceutical sector.